Dr. Bassem I. Razzouk, MD
Pediatric Hematology & Oncology (Pediatric Hematology & Oncology Physician)
At a glance
- Years since graduation
- 39
- In the NPI registry since
- 2005
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Hematology & Oncology Physician primary
IN license 01063092A
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- St Vincent Pediatric Subspecialties (36 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Payments from drug and device companies
In 2025, 2 companies reported 17 payments worth $17,949 in total to this clinician.
| Jazz Pharmaceuticals Inc. | $17,719 |
|---|---|
| Amgen Inc. | $230 |
| Compensation for services other than consulting (speaking, faculty) | $14,570 |
|---|---|
| Travel and Lodging | $2,613 |
| Food and Beverage | $766 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Jazz Pharmaceuticals Inc. May 12, 2025 | Compensation for services other than consulting (speaking, faculty) RYLAZE · HEMATOLOGY/ONCOLOGY | $4,960 |
| Jazz Pharmaceuticals Inc. Oct 15, 2025 | Compensation for services other than consulting (speaking, faculty) RYLAZE · HEMATOLOGY/ONCOLOGY | $4,960 |
| Jazz Pharmaceuticals Inc. Nov 17, 2025 | Compensation for services other than consulting (speaking, faculty) RYLAZE · HEMATOLOGY/ONCOLOGY | $3,720 |
| Jazz Pharmaceuticals Inc. May 5, 2025 | Travel and Lodging RYLAZE · HEMATOLOGY/ONCOLOGY · travel to Akron, OH · in-kind | $1,689 |
| Jazz Pharmaceuticals Inc. Oct 14, 2025 | Compensation for services other than consulting (speaking, faculty) RYLAZE · HEMATOLOGY/ONCOLOGY | $930 |
| Jazz Pharmaceuticals Inc. Aug 9, 2025 | Travel and Lodging RYLAZE · HEMATOLOGY/ONCOLOGY · travel to Pittsburgh, PA · in-kind | $376 |
| Jazz Pharmaceuticals Inc. Oct 10, 2025 | Travel and Lodging RYLAZE · HEMATOLOGY/ONCOLOGY · travel to Pittsburgh, PA · in-kind | $375 |
| Jazz Pharmaceuticals Inc. Oct 22, 2025 | Travel and Lodging RYLAZE · HEMATOLOGY/ONCOLOGY · travel to Pittsburgh, PA · in-kind | $157 |
| Jazz Pharmaceuticals Inc. Nov 24, 2025 | Travel and Lodging RYLAZE · HEMATOLOGY/ONCOLOGY · travel to Indianapolis, IN · in-kind | $15.40 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $6,000 in research payments for these studies, mostly to the institutions running them.
- A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 M…
Jazz Pharmaceuticals Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.